Osteoporosis: A Tale of 3 Task Forces!
|
|
- Britney Mathews
- 6 years ago
- Views:
Transcription
1 Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA
2 Disclosures The opinions are those of the speaker and not necessarily those of the Department of Veterans Affairs
3 Topics and Task Forces ASBMR Long Term Bisphosphonates for Osteoporosis AACE Postmenopausal Osteoporosis Guideline ACR Guideline for Glucocorticoid-Induced Osteoporosis
4 American College of Rheumatology - GIOP Categorizes patients by age and by fracture risk (FRAX) For patients on > 2.5 mg of prednisone equivalent daily High dose = > 30 mg/day or > 5 grams/year. For discussion, focus on adults only Very evidence based Disclosure: Membership on expert panel that helped develop the PICO (population/intervention/comparator/outcomes) questions. L Buckley, Arthritis Care Res 2017; doi /acr.23279
5 ACR-GIOP: Definition - High Risk Adults > 40 Years Old Prior osteoporotic Fracture BMD < -2.5 (spine, hip) for postmenopausal women, men > 50 years old FRAX MOF > 20% FRAX Hip > 3% Adults < 40 Years Old Prior osteoporotic fracture
6 ACR-GIOP: Definition - Moderate Risk Adults > 40 Years Old FRAX MOF 10-19% FRAX Hip > 1% < 3% Adults < 40 Years Old BMD (spine, hip) Z-score < -3 OR > 10% loss in 1 year AND > 7.5 mg Prednisone Equivalent for > 6 months
7 ACR-GIOP: Definition -Low Risk on GC Adults > 40 Years Old No osteoporotic fractures FRAX MOF < 10% FRAX Hip < 1% Adults < 40 Years Old No osteoporotic fractures
8 ACR-GIOP: First Evaluation Adults > 40 Years Old FRAX with GC Dose Correction BMD within 6 months of GC Rx Adults < 40 Years Old BMD within 6 months of GC Rx IF h/o osteoporotic fracture OR other risk factors
9 FRAX Correction for GC Dose For GC Dose > 7.5 mg Prednisone Equivalent/Day: Multiply MOF Risk by 1.15 Multiply Hip Risk by 1.2 L Buckley Arthritis Care Res 2017; doi /acr.23279
10 Re-Assessment: Patients < 40 Years Old Clinical assessment every year BMD every 2 or 3 years only if: History of Osteoporotic Fracture OR Z-score < -3 at hip or spine OR > 10%/year loss at spine or hip BMD OR Very high dose GC Rx OR Other osteoporosis risk factors
11 Re-Assessment: Patients > 40 Years Old Clinical re-assessment every year If no h/o treatment FRAX every 1-3 years with BMD if available Clinical assessment yearly If OP Rx has been completed (e.g. patient stopped GC) BMD every 2-3 years
12 Re-Assessment: Patients > 40 Years Old Clinical re-assessment every year While on Osteoporosis Treatment, BMD every 2-3 years ONLY IF: Very high dose GC OR OP Fracture at least 18 months after starting OP Rx OR Poor medication adherence OR Other Osteoporosis risk factors
13 Initial Rx: For All Adults including Low Risk Adults > 40 years old Calcium intake of mg/day, preferably in diet Vitamin D units/day Smoking cessation, limit EtOH Weight bearing or resistance exercise
14 Initial Rx: Moderate Risk: Adults > 40 years old Add oral bisphosphonates Prefer to: IV bisphosphonates more risk Teriparatide cost and injection burden Denosumab lack of safety data in immunosuppressed patients Raloxifene lack of data in GIOP and potential clotting harms
15 Initial Rx: High Risk Adults > 40 years old Add oral bisphosphonate Prefer to: IV Bisphosphonate more risk Teriparatide cost and injection burden Denosumab lack of safety data in immunosuppressed patients Raloxifene lack of data in GIOP and potential clotting harms
16 Initial Rx: Low Risk Patients < 40 Years Old Dietary Calcium Vitamin D Exercise
17 Initial Rx: Moderate to High Risk < 40 Y.O. Add oral bisphosphonate Prefer to: IV Bisphosphonate higher risk profile Teriparatide cost and injection burden Denosumab lack of safety data in immunosuppressed patients
18 Rx in Women of Childbearing Potential at Moderate to High Risk Add oral bisphosphonate Second line Rx: teriparatide Third line: IV bisphosphonates, teriparatide Use contraception
19 What Ifs for Patients > 40 Years Old If Fracture or 10%/year bone loss after 18 months of oral bisphosphonate and still on GC Teriparatide or denosumab or IV bisphosphonate If still on GC after 5 years of oral bisphosphonate Continue oral bisphosphonate or switch to IV or other Rx If off GC and now at low risk Stop oral bisphosphonate, continue calcium and D If off GC but still at moderate to high risk Complete course of osteoporosis Rx
20 Pathophysiology of GIOP Early increase in bone resorption Early and profound decrease in bone formation Increase of fracture risk as early as 3 months of GC Rx Osteoblasts are turned off: Anabolics turn on osteoblasts Other pathophysiology less important Decreased muscle strength Hypercalciuria Hypogonadism
21 Teriparatide vs. Alendronate in GIOP 3 Year Study in 428 women and men Fracture Type Alendronate (n = 214) TPTD (n =214) P Value > 1 morphometric vertebral > 1 clinical vertebral (n = 169/173) 13 (7.7%) 3 (1.7%) < (2.4%) 0 < 0.05 > 1 non-vertebral 15 (7.0%) 16 (7.5%) NS > 1 non-vertebral fragility 5 (2.3%) 9 (4.2) NS KG Saag Arthritis Rheum 60:3346, 2009
22 ACR-GIOP Conclusions 15 Slides to Explain Guideline Who is going to read it? Many docs prescribe glucocorticoids! Not much different from 2010 version Value judgement in preferring oral bisphosphonates Chose to ignore pathophysiology of GIOP and apparent superiority of anabolic Rx for high risk patients.
23 New Findings in GIOP Increased risk of fracture with short courses of GC Effects of inhaled glucocorticoids Use of denosumab (off label) in GIOP Alendronate decreases hip fracture risk in GIOP Lack of adherence to GIOP Guidelines
24 Fracture Risk May Increase Within 1 Month! Observational study from large insurance database / adults receive a short course of GC (<30 days) Fracture Risk 1.87 ( ) on days 5-30 Risk gradually decreased in days AK Waljee, BMJ 2017;357:j1415
25 Inhaled GC and GIOP In asthma: higher GC doses higher fracture risk In COPD: less dose response Short courses of oral glucocorticoids are common in patients on inhaled glucocorticoids! SA Sutter, Curr Osteoporos Rep 14:106, 2016
26 Denosumab in GIOP (off label) Small studies show that denosumab increases bone density in spine and hip in GIOP No fracture data yet M Sawamura, Intern Med 56:631, 2017; S Ishiguro, Arch Osteoporos 12:44, 2017
27 Alendronate decreased hip fractures Retrospective cohort study >65 years; >5mg prednisolone for >3 months 1802 had Rx for alendronate 50 after at least 3 months of GC propensity-matched 30 controls no alendronate 20 Follow up median: 1.32 years 10 0 Following Guideline worked! No ALN Fractures ALN Fractures KF Axelsson, JAMA 318:146, 2017
28 Improving Adherence to GIOP Guideline Interventions aimed at patients Interventions aimed at providers Interventions aimed at both System-wide interventions G Mazziotti, Endocrine 54:603, 2016
29 Patient Video Patients with online prescription program Video automatically came up at time of refill versus no video at time of refill 59% viewed at least some of the video No change in receiving osteoporosis Rx. AH Warriner, J Rheumatol 42:1478, 2015
30 Videos for Patients 2.95 % Rx % Rx Video No Video AH Warriner J Rheumatol 42:1478, 2015
31 Multifaceted Intervention Rheumatologists randomized to: Lecture, Audit, and Reminder Mailing OR No intervention No increase in DXAs ordered No increase in osteoporosis Rx DH Solomon, Arthritis Rheum 51:383, 2004
32 Effect of Education Education % Rx No Education % Rx DH Solomon Arthritis Rheum 51:383, 2004
33 Where to Look for the Answer: It s in the old literature!
34 Geisinger Clinic Plan Three Sources to Identify GIOP Patients Self referral (advertisements in clinics) Clinician referral (via electronic record) Database search by Nurse Make the FLS Nurse be the GIOP Nurse! Dramatic DXA and Rx ED Newman, Osteoporos Int 17:1428, 2006
35 Change in Rx % Rx Baseline All - 6 months All - 1 year Hi Risk - 6 mo. Hi Risk - 1 yr. % Rx ED Newman, Osteoporos Int 17:1428, 2006
36 Suggested Approach Have the FLS Nurse become the GIOP Nurse Get approval from clinicians Once weekly printout of new GC Rxs Contact the patients (similar to FLS) Assess fracture risk by history Order a DXA Assure adequate calcium and D Start treatment Alert the primary clinician
37
38
39 Long Term Bisphosphonate Rx J Bone Miner Res 31:16-35, 2016
40
41
42 Adler s Approach: Duration of Bisphosphonate Rx 5 years of oral Rx for high fracture risk i.v. zoledronic acid q months = 5 years of Rx Clinical assessment annually; DXA at 2-3 years At 5 years, assess fracture risk again DXA (T < -2.5), history of fracture Side effects risks predictable? Other factors Meds (e.g. continuing glucocorticoids, ADT, Aromatase Inhibitors) Falling and frailty Competing causes of mortality Assess again periodically RA Adler J Bone Miner Res 31:16, 2016; RA Adler Endocrine 51: 222, 2016 J Ward Osteoporos Int 27:2681, 2016; A Gustafsson Bone 88:125, 2016
43 Reduced Bisphosphonate Prescription Rates Starting in 2008 S Jha, J Bone Miner Res. 2015;30:
44 Nonadherence Must take 75-80% of Rx in order to show fracture ~50% of patients still on Rx at 1 year Reasons for poor adherence No symptoms: osteoporosis is silent until fracture Complex dosing regimens Cost no longer a problem Concern about side effects MI Williams & VI Petkov in RA Adler, ed, Osteoporosis-2nd Ed, 2010.
45 DXA, Diagnosis, Reimbursement 26% 24% Percent of Women Age % 20% 18% 16% 14% 12% DXA Medicare Payments $139 Osteoporosis Diagnosis DXA Testing $ % 17.9% $ % 10% 11.3% Direct Research LLC, Medicare PSPS Master Files and Medicare 5 Percent Sample LDS SAF, analysis by Peter M. Steven, PhD.
46 No More Hip Fracture Rate 26% Hip Fracture Rates 900 Percent of Women Age % 22% 20% 18% 16% 14% 12% 884 DXA Medicare Payments $139 Osteoporosis Diagnosis DXA Testing $ % 17.9% % $ Fractures per 100,000 Women Age 65+ Age-adjusted to the 2014 Age Distribution 10% 11.3% 500 Direct Research LLC, Medicare PSPS Master Files and Medicare 5 Percent Sample LDS SAF, analysis by Peter M. Steven, PhD.
47 Drug Prices Per Month Drug U.S. Retail U.S. Veterans Denmark Italy Alendronate - Weekly Risedronate - Monthly Zoledronic Acid Annually Denosumab Q 6 months Teriparatide Daily
48 New Paradigm? How would you treat the high risk patient if: All osteoporosis meds cost the same as generic oral alendronate? Could be prescribed without jumping through hoops? Patient care was based on what is best for the patient?
49 Future Rx for GIOP and Other High Risk? Anabolics first in many cases Add an anti-resorptive Then, after some months, d/c anabolic Re-introduce anabolic temporarily after some period (2-3 years?) while continuing anti-resorptive Do a femoral shaft x-ray on DXA every year
50 DATA-SWITCH Study BZ Leder, Lancet 386:1147, 2015
51 DATA Follow Up Study 0-1 Lumbar Sp Total Hip Fem Neck No Rx Any Rx BZ Leder, Bone 98:54, 2017
52 Vert Fx 8-16 months after Stopping Denosumab: 112 Fractures in 24 Women AD Anastasilakis J Bone Miner Res 32:1291, 2017
53 From: Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisA Randomized Clinical Trial JAMA. 2016;316(7): doi: /jama Date of download: 4/17/2017 Copyright 2017 American Medical Association. All rights reserved.
54 From: Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisA Randomized Clinical Trial JAMA. 2016;316(7): doi: /jama Date of download: 4/17/2017 Copyright 2017 American Medical Association. All rights reserved.
55 From: Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisA Randomized Clinical Trial Date of download: 4/17/2017 Copyright 2017 American Medical Association. All rights reserved.
56 LS: Abalo vs. PLO X 18 mos; then ALN AB then ALN PLO then ALN months 12 months 18 months 25 months F Cosman Mayo Clin Proc 92:200, 2017
57 Non-Pharmacologic Rx Attain Maximal Skeletal Growth Calcium + Vitamin D Fracture Risk Fall Risk Reduction Improve lower body muscle strength Tai chi, yoga, weight-bearing exercise Good vision Walking aids Home safety CM Weaver, Osteoporos Int 27: 367, 2016
58 Maximize the Benefit/Risk Ratio Find the patients most likely to benefit Previous fragility fracture a sentinel event! Glucocorticoids Aromatase inhibitors, ADT, etc. Find those at particular risk for hip fracture Older women hip fracture: 15-20% 1 year mortality Older men hip fracture: 25-35% 1 year mortality Those that survive: half lose independence!
59 ?Minimize Risks for Side Effects? ONJ Poor dental hygiene Invasive dental procedure (e.g., extraction) Atypical Femoral Fractures Active younger woman with osteopenia? East Asian ethnicity? Femoral geometry? Varus angle of femoral neck and shaft? Bowing of femur? Image on DXA machine every year? Z Mahjoub J Bone Miner Res 31:767, 2016; JC Lo Bone 85:142, 2016
60 Long Term Rx: Adler s Approach 2017 Test: Is the patient at risk for fracture? Find patients at risk Test: Mitigate risk factors for side effects? Treat the patient with highest Benefit/Risk Treat in the correct sequence Tell the patient: plan for 5 years of Rx Test again after 2-3 years of Rx Test again at 5 years Talk to the patient at 5 years Test again every 2 years RA Adler, Endocrine 51:222, 2016
Osteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationOsteoporosis TreatmentUpdate November 2018
Osteoporosis TreatmentUpdate November 2018 Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures Opinions are those of the speaker
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationTalking to patients with osteoporosis about initiating therapy
Talking to patients with osteoporosis about initiating therapy Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationPage 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationOsteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Osteoporosis in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationHealthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C
Healthy Bones: Osteoporosis Management Laurel Short, MSN, FNP-C Disclosure I have no current affiliation or financial interest with any grantor or commercial interests that may have direct interest in
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationOsteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic
Osteoporosis 2017 Breaking News Julie L. Carkin, MD The Seattle Arthritis Clinic 1 Yes, Hopefully & No Anabolic Teriparatide Abaloparatide Romosozumab blosozumab Anti-catabolic Bisphosphonates Denosumab
More informationAn Update on Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
An Update on Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Joseph Flood, MD, FACR, CCD President, Musculoskeletal Medical Specialists, Inc. Clinical Assistant Professor of Internal Medicine
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationUpdated Guidelines from NOF, NBHA, ISCD, IOF
Updated Guidelines from NOF, NBHA, ISCD, IOF October 11-12, 2018 E. Michael Lewiecki, MD, FACP, FACE Director, New Mexico Clinical Research & Osteoporosis Center Director, Bone Health TeleECHO University
More informationFRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment
These guidelines are endorsed by the following Lebanese Scientific Societies and Associations: Lebanese Society of Endocrinology Diabetes and Lipids, Lebanese Society of Rheumatology, Lebanese Society
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationA Brief History of Osteoporosis
Challenges in the Treatment of Osteoporosis Disclosure Institutional Grant / Research Support Amgen Consulting Amgen, Radius, Shire, Alexion Speaking Shire, Alexion E. Michael Lewiecki, MD New Mexico Clinical
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More informationOsteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists
Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationDisclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?
Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E.
More informationScreening Guidelines: Women
The Situation 1 in 2 postmenopausal women and 1 in 5 older men will have an osteoporosis-related fracture in their lifetimes Osteoporosis Definition NIH Consensus Conference A skeletal disorder characterized
More informationGuidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationOsteoporosis Physician Performance Measurement Set. October 2006
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More information